Dermatomyositis predominates among checkpoint inhibitor-associated inflammatory myositis phenotypes: a pharmacovigilance disproportionality analysis identifies a class-wide signal.

Abstract excerpt

ICI-induced inflammatory myositis (IIM) is a recognized irAE with significant morbidity and potential for life-threatening overlap syndromes. Whether polymyositis (PM) and dermatomyositis (DM) carry differential pharmacovigilance signals across ICI drug classes has not been systematically examined. A disproportionality analysis of FAERS was conducted to quantify reporting odds ratios across twelve approved ICI...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Dermatomyositis
• Share to Immune Checkpoint Inhibitors